BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer

February 8, 2023

https://www.globenewswire.com/news-release/2023/02/08/2603791/0/en/BioXcel-Therapeutics-to-Host-BXCL701-Key-Opinion-Leader-Day-to-Highlight-Company-s-Investigational-Oral-Innate-Immune-Activator-for-Rare-Form-of-Prostate-Cancer.html

NEW HAVEN, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq:BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a Key Opinion Leader (KOL) Day focused on its lead immuno-oncology program BXCL701 for the investment community on Tuesday, February 21, 2023 from 1:00 to 3:00 p.m. ET.

Read more at globenewswire.com

Related news for (BTAI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.